International Journal of Medical Laboratory Research (IJMLR)

AUDIT OF ANTIEMETIC DRUG PRESCRIPTION AND THEIR EFFECT IN AMELIORATING NAUSEA AND VOMITING IN PEOPLE UNDERGOING CURATIVE CHEMOTHERAPY FOR THEIR CANCER: OBSERVATIONS FROM A TERTIARY CARE CENTRE

 

SA D’silva, PL Palatty, R Tonse, P Simon, P D’silva, S Rao, MS Baliga

 

ABSTRACT: Background: In the treatment of cancer with chemotherapy, the drug induced nausea and vomiting (NIV) is an important side effect and in severe conditions can hamper the therapy. In this study an attempt is made to understand the prescription pattern of the various antiemetic regimens and their efficacy in ameliorating both NIV and the quality of life. Methods: In the study 68 patients were initially included of which 60 completed all the proposed 6 cycles of chemotherapy. The extent of nausea and vomiting and the effect of the same on the quality of life of the patients were assessed using a questionnaire, which was filled at various time points (0, 6, 24 and 120 hrs) following the initiation of the chemotherapy. Results: Comparison of the mean of the various parameters showed that the mean age of the patients enrolled was 47.55 ± 9.893 with 73.3% being females and 26.78% being males. The most common type of cancer in this study was Ca breast (35%). Palonosetron was the most common antiemetic used (63.3%), followed by aprepitant, granisetron and ondansetron. Dexamethasone was prescribed to all patients. Patients who were on antiemetic regimens which didn’t include aprepitant complained of acute (75%) and delayed nausea (6%), as well as acute (45%) and delayed emesis (5%). Patients who received aprepitant had complete response (no nausea, no emesis) (100%). The quality of life parameters of patients was not affected significantly. Conclusion: The combinations of aprepitant + palonosetron + dexamethasone and aprepitant + dexamethasone were most commonly preferred and achieved reasonable effectiveness.

 

KEY WORDS: cancer chemotherapy-induced nausea and vomiting, chemotherapy, anti-emetics, palonosetron, aprepitant, acute and delayed nausea, acute and delayed emesis.

​

REFERENCES:

1. Bošnjak SM, Gralla RJ, Schwartzberg L. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK(1)) receptor antagonists. Support Care Cancer. 2017; 25(5):1661-1671

2. Gilmore J, D'Amato S, Griffith N, Schwartzberg L. Recent advances in antiemetics: new formulations of 5HT(3)-receptor antagonists. Cancer Manag Res. 2018; 10:1827-1857.

3. Shelke AR, Mustian KM, Morrow GR. The pathophysiology of treatment –related nausea and vomiting in cancer patients: current models. Indian J physiolpharmacol2004; 48(3):256-268.

4. Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic ClinPharmacolToxicol. 2007;101:143–50

5. PDQ Supportive and Palliative Care Editorial Board. Treatment-Related Nausea and Vomiting (PDQ®): Health Professional Version. 2018 Nov 5. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. Available from http:// www. ncbi. nlm. nih.gov/ books/ NBK66056/

6. Marx W, Kiss N, McCarthy AL, McKavanagh D, Isenring L. Chemotherapy-Induced Nausea and Vomiting: A Narrative Review to Inform Dietetics Practice. J Acad Nutr Diet. 2016; 116(5):819-27.

7. Hesketh PJ. Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice The Oncologist 1999;4(3):191-196

8. Lee S. Schwartzberg. Chemotherapy-Induced Nausea and Vomiting: Which Antiemetic for Which Therapy. Oncology, 2007;21:8

9. Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer 2005; 104(4): 864-8.

10. Hesketh PJ, Sanz-Altamira P. Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea andvomiting.Support Care Cancer. 2012; 20(3): 653-6.

11. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004; 15(2):330-7.

12. Osorio-Sanchez JAA, Karapetis C, Koczwara B. (2007), Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting. Int Med J, 37: 247–250.